A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
- Angela Dispenzieri
- , Efstathios Kastritis
- , Ashutosh D. Wechalekar
- , Stefan O. Schönland
- , Kihyun Kim
- , Vaishali Sanchorawala
- , Heather J. Landau
- , Fiona Kwok
- , Kenshi Suzuki
- , Raymond L. Comenzo
- , Deborah Berg
- , Guohui Liu
- , Arun Kumar
- , Douglas V. Faller
- , Giampaolo Merlini
- Mayo Clinic Rochester, MN
- National and Kapodistrian University of Athens
- University College London
- Heidelberg University
- Boston University
- Memorial Sloan-Kettering Cancer Center
- Westmead Hospital
- Japanese Red Cross Medical Center
- Tufts Medical Center
- Takeda Pharmaceutical Company Limited
- University of Pavia
Research output: Contribution to journal › Article › peer-review
58
Link opens in a new tab
Scopus
citations